On December 12, the 10th National Volume-Based Drug Procurement (VBP) tender was held in Shanghai. Shandong Qidu Pharmaceutical Co., Ltd. had five products successfully selected:
1. Ciprofloxacin Lactate and Sodium Chloride Injection
2. Pentoxifylline Injection
3. Sodium Bicarbonate Ringer's Injection
4. Sodium Lactate Ringer's Injection
5. Potassium Chloride Injection
Product Details
1. Ciprofloxacin Lactate and Sodium Chloride Injection
- Specification: 100ml:0.2g:0.9g
- Packaging: Polypropylene (PP) infusion bottle
- Features:
- One of the most potent fluoroquinolone antibiotics against Pseudomonas aeruginosa
- Widely used for skin/soft tissue infections, bone/joint infections, intra-abdominal infections, respiratory infections, and genitourinary infections
- Broad-spectrum, excellent tissue penetration, and high efficacy
- Listed in China National Reimbursement Drug List (NRDL) Class B and National Essential Medicines List
2. Pentoxifylline Injection
Specification: 5ml:0.1g
Packaging: PP ampoule
Features:
- A non-specific peripheral vasodilator with multiple mechanisms (vasodilation, microcirculation improvement, antiplatelet aggregation)
- Used for cerebral/peripheral circulatory disorders and inner ear blood flow issues
- Listed in NRDL Class B
3. Sodium Bicarbonate Ringer's Injection
Specification: 500ml
Packaging: Multi-layer co-extruded IV bag with outer barrier
Features:
- A plasma-adapted compound electrolyte solution for extracellular fluid replenishment
- Corrects metabolic acidosis during hypovolemia
- Listed in NRDL Class B
4. Sodium Lactate Ringer's Injection
Specification: 500ml
Packaging: PP infusion bottle
Features:
- Regulates fluid, electrolyte, and acid-base balance
- Treats metabolic acidosis and dehydration
- High safety, minimal side effects, and ease of use
- Listed in NRDL Class A and National Essential Medicines List
5. Potassium Chloride Injection
- Specification: 10ml:1.5g
- Packaging: PP ampoule
- Features:
- Electrolyte supplement for hypokalemia treatment/prevention
- Manages digoxin-induced arrhythmias
- Listed in NRDL Class A and National Essential Medicines List
Manufacturing Capabilities
Qidu Pharma boasts annual production capacities of:
- 2 billion bottles/bags of large-volume injections
- 1 billion units of PP ampoule small-volume injections
Advanced Production Technologies
- Large-Volume Injections:
- China's most advanced production facility with fully digitized processes
- Integrated MES, WMS, DMS, LIMS, and drug traceability systems for end-to-end quality control
- Small-Volume Injections (PP Ampoules):
- Uses Blow-Fill-Seal (BFS) technology for one-step sterile molding
- Superior to traditional glass ampoules: no particulates, easy to open, shatterproof, and contamination-resistant
Strategic Impact
The selection of these five products in the 10th VBP round will:
✔ Optimize market structure
✔ Enhance brand influence and competitiveness
✔ Provide better treatment options for clinicians and patients
-
Previous:
Qidu Pharmaceutical's Compound Glucose/Electrolyte Craniocerebral Surgery Irrigation Solution becomes the first generic drug approved for market in China
-
Next:
The Large-Volume Injection Production Project with an Annual Output of 1 Billion Bottles/Bags Fully Completed and Put into Operation
Recommended reading
-
January 20, 2025Top Ten Events of Qidu Pharmaceutical Group in 2025 Announced
-
June 17, 2026Qidu Pharma’s intelligent production project for oral preparations with an annual capacity of 10 billion tablets/granules passed the GMP on-site inspection.
-
June 25, 2026Qidu Biotech Approved to Establish "Zibo (Qidu) Cell Preparation Center and Tissue Cell Bank"
-
June 23, 2026Zheng Jiaqing was honored as a National Model Worker
-
June 23, 2026Qidu Pharma was designated as one of the “National Outstanding Excellence-Level Smart Factories”
-
June 23, 2026Qidu Pharma was included in the “Shandong Top 100 Private Enterprises” series of rankings.
-
June 23, 2026Qidu Pharma was listed among China’s top 100 pharmaceutical companies by main business revenue.